Guggenheim Capital LLC Amylyx Pharmaceuticals, Inc. Transaction History
Guggenheim Capital LLC
- $13.9 Billion
- Q2 2024
A detailed history of Guggenheim Capital LLC transactions in Amylyx Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 15,448 shares of AMLX stock, worth $76,622. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,448
Previous 16,338
5.45%
Holding current value
$76,622
Previous $46,000
36.96%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding AMLX
# of Institutions
139Shares Held
46.5MCall Options Held
226KPut Options Held
909K-
Vanguard Group Inc Valley Forge, PA4.22MShares$21 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT3.34MShares$16.6 Million0.01% of portfolio
-
Black Rock Inc. New York, NY2.67MShares$13.2 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY2.61MShares$12.9 Million0.0% of portfolio
-
Abrdn PLC1.97MShares$9.78 Million0.01% of portfolio
About Amylyx Pharmaceuticals, Inc.
- Ticker AMLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,533,200
- Market Cap $290M
- Description
- Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...